Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 4/20 | 0.43 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.43 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.42 |
| ▸ | ACHE | P22303 | 2/20 | 0.42 |
| ▸ | DRD4 | P21917 | 1/20 | 0.41 |
| ▸ | MC4R | P32245 | 1/20 | 0.41 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
| ▸ | BCHE | P06276 | 1/20 | 0.40 |
| ▸ | BACE1 | P56817 | 1/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | FPR2 | P25090 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | LTA4H | P09960 | 2/20 | 0.39 |
| ▸ | HTR1A | P08908 | 1/20 | 0.39 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.39 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.39 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20522837 | 1.00 | TACR1 (0.43) | TACR1CHRM3CHRM2SIGMAR1ACHE | |
| SCHEMBL24912591 | 1.00 | TACR1 (0.43) | TACR1CHRM3CHRM2SIGMAR1ACHE | |
| SCHEMBL21909641 | 0.89 | ALDH1A1 (0.42) | ACHEBCHEBACE1OPRM1LMNA | |
| SCHEMBL7838918 | 0.80 | SIGMAR1 (0.46) | TACR1CHRM3CHRM2SIGMAR1ACHE | |
| SCHEMBL2668698 | 0.79 | LTA4H (0.57) | TACR1CHRM3CHRM2SIGMAR1ACHE | |
| SCHEMBL24649078 | 0.79 | LTA4H (0.57) | TACR1CHRM3CHRM2SIGMAR1ACHE | |
| SCHEMBL21124809 | 0.78 | FUCA1 (0.47) | SIGMAR1ACHEDRD4MC4RDRD2 | |
| SCHEMBL2659902 | 0.76 | TACR1 (0.48) | TACR1CHRM3CHRM2SIGMAR1ACHE | |
| SCHEMBL20522860 | 0.76 | TACR1 (0.48) | TACR1CHRM3CHRM2SIGMAR1ACHE | |
| SCHEMBL13898835 | 0.74 | CHRM3 (0.56) | CHRM3CHRM2ACHEDRD4DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3601297-B9 | COMPOUNDS THAT INHIBIT MCL-1 PROTEIN | AMGEN INC (US) | 2023-05-24 | — | — | EP | disclosed |
| EP-3601297-B1 | COMPOUNDS THAT INHIBIT MCL-1 PROTEIN | AMGEN INC (US) | 2022-10-19 | — | — | EP | disclosed |
| US-11224601-B1 | Compounds that inhibits MCL-1 protein | AMGEN INC. (US) | 2022-01-18 | — | — | US | disclosed |
| US-11224601-B1 | Compounds that inhibits MCL-1 protein | AMGEN INC. (US) | 2022-01-18 | — | — | US | disclosed |
| US-10821115-B2 | Compounds that inhibit Mcl-1 protein | AMGEN INC. (US) | 2020-11-03 | — | — | US | disclosed |
| US-10821115-B2 | Compounds that inhibit Mcl-1 protein | AMGEN INC. (US) | 2020-11-03 | — | — | US | disclosed |
| US-20200171043-A1 | COMPOUNDS THAT INHIBIT MCL-1 PROTEIN | AMGEN INC. (US) | 2020-06-04 | — | — | US | disclosed |
| US-20200171043-A1 | COMPOUNDS THAT INHIBIT MCL-1 PROTEIN | AMGEN INC. (US) | 2020-06-04 | — | — | US | disclosed |
| US-10632128-B2 | Compounds that inhibit Mcl-1 protein | AMGEN INC. (US) | 2020-04-28 | — | — | US | disclosed |
| EP-3601297-A1 | COMPOUNDS THAT INHIBIT MCL-1 PROTEIN | Amgen Inc. (US) | 2020-02-05 | — | — | EP | disclosed |
| US-20190201412-A1 | COMPOUNDS THAT INHIBIT MCL-1 PROTEIN | AMGEN INC. (US) | 2019-07-04 | — | — | US | disclosed |
| US-10300075-B2 | Compounds that inhibit MCL-1 protein | AMGEN INC. (US) | 2019-05-28 | — | — | US | disclosed |
| US-10300075-B2 | Compounds that inhibit MCL-1 protein | AMGEN INC. (US) | 2019-05-28 | — | — | US | disclosed |
| US-20180289720-A1 | COMPOUNDS THAT INHIBIT MCL-1 PROTEIN | AMGEN INC. (US) | 2018-10-11 | — | — | US | disclosed |
| WO-2018183418-A1 | COMPOUNDS THAT INHIBIT MCL-1 PROTEIN | AMGEN INC. (US) | 2018-10-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190201412-A1 | COMPOUNDS THAT INHIBIT MCL-1 PROTEIN | MCL1, BCL9, BCL2L1 | TACR1 4845/4885CHRM3 4882/4885CHRM2 4881/4885 |
| US-10821115-B2 | Compounds that inhibit Mcl-1 protein | MCL1, BCL9, BCL2L1 | TACR1 4845/4885CHRM3 4882/4885CHRM2 4881/4885 |
| US-20180289720-A1 | COMPOUNDS THAT INHIBIT MCL-1 PROTEIN | MCL1, BCL9, BCL2L1 | TACR1 4845/4885CHRM3 4882/4885CHRM2 4881/4885 |
| US-10632128-B2 | Compounds that inhibit Mcl-1 protein | MCL1, BCL9, BCL2L1 | TACR1 4845/4885CHRM3 4882/4885CHRM2 4881/4885 |
| US-10300075-B2 | Compounds that inhibit MCL-1 protein | MCL1, BCL9, BCL2L1 | TACR1 4845/4885CHRM3 4882/4885CHRM2 4881/4885 |
| US-20200171043-A1 | COMPOUNDS THAT INHIBIT MCL-1 PROTEIN | MCL1, BCL9, BCL2L1 | TACR1 4845/4885CHRM3 4882/4885CHRM2 4881/4885 |
| US-11224601-B1 | Compounds that inhibits MCL-1 protein | MCL1, BCL9, BCL2L1 | TACR1 4842/4885CHRM3 4882/4885CHRM2 4881/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.